HIMS has been crushed this year, down about 50% year-to-date to around $7.05. The main issue is their GLP-1 weight loss business. They stopped offering a compounded Wegovy pill after comments from the FDA and a patent lawsuit from Novo Nordisk. They just reported Q4 earnings. Revenue was up 28% to $617.8M and EPS came in at $0.08, which beat the $0.05 consensus. However, gross margins dropped to 72% and their Q1 revenue guidance missed estimates ($600-625M range vs $647.9M expected). They also announced they're acquiring Eucalyptus for international expansion.